APO RESEARCH · REPORT
Cyclophosphamide
Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.
Product & engineering
Understand the product.
Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.
Selected research
Market Structure
Global Cyclophosphamide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.
Top 8 manufacturers took 75.4% market share in 2019.
This report provides an overview of the global Cyclophosphamide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Cyclophosphamide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cyclophosphamide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cyclophosphamide market size, projected growth trends, production technologies, key applications, and end-use industries.
Cyclophosphamide Segment by Company
Baxter
Novartis
Hikma Pharmaceuticals
Amneal Pharmaceuticals LLC
Jiangsu Hengrui Medicine
NorthStar Rx LLC
GLS Pharma
CSC Pharmaceuticals International
Cyclophosphamide Segment by Type
High-Dose
Low-Dose
Cyclophosphamide Segment by Application
Cancer
Autoimmune Diseases
AL Amyloidosis
Others
Cyclophosphamide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclophosphamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyclophosphamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclophosphamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Cyclophosphamide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cyclophosphamide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cyclophosphamide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Cyclophosphamide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- High-Dose
- Low-Dose
Applications
- Cancer
- Autoimmune Diseases
- AL Amyloidosis
- Others
Companies covered
- Baxter
- Novartis
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Jiangsu Hengrui Medicine
- NorthStar Rx LLC
- GLS Pharma
- CSC Pharmaceuticals International
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cyclophosphamide Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cyclophosphamide Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Cyclophosphamide Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Cyclophosphamide Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Cyclophosphamide Market Dynamics
- 2.1 Cyclophosphamide Industry Trends
- 2.2 Cyclophosphamide Industry Drivers
- 2.3 Cyclophosphamide Industry Opportunities and Challenges
- 2.4 Cyclophosphamide Industry Restraints
3 Cyclophosphamide Market by Manufacturers
- 3.1 Global Cyclophosphamide Revenue by Manufacturers (2021-2026)
- 3.2 Global Cyclophosphamide Sales by Manufacturers (2021-2026)
- 3.3 Global Cyclophosphamide Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Cyclophosphamide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Cyclophosphamide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Cyclophosphamide Manufacturers, Product Type & Application
- 3.7 Global Cyclophosphamide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Cyclophosphamide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Cyclophosphamide Players Market Share by Revenue in 2025
- 3.8.3 2025 Cyclophosphamide Tier 1, Tier 2, and Tier 3
4 Cyclophosphamide Market by Type
- 4.1 Cyclophosphamide Type Introduction
- 4.1.1 High-Dose
- 4.1.2 Low-Dose
- 4.2 Global Cyclophosphamide Sales by Type
- 4.2.1 Global Cyclophosphamide Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cyclophosphamide Sales by Type (2021-2032)
- 4.2.3 Global Cyclophosphamide Sales Market Share by Type (2021-2032)
- 4.3 Global Cyclophosphamide Revenue by Type
- 4.3.1 Global Cyclophosphamide Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Cyclophosphamide Revenue by Type (2021-2032)
- 4.3.3 Global Cyclophosphamide Revenue Market Share by Type (2021-2032)
5 Cyclophosphamide Market by Application
- 5.1 Cyclophosphamide Application Introduction
- 5.1.1 Cancer
- 5.1.2 Autoimmune Diseases
- 5.1.3 AL Amyloidosis
- 5.1.4 Others
- 5.2 Global Cyclophosphamide Sales by Application
- 5.2.1 Global Cyclophosphamide Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cyclophosphamide Sales by Application (2021-2032)
- 5.2.3 Global Cyclophosphamide Sales Market Share by Application (2021-2032)
- 5.3 Global Cyclophosphamide Revenue by Application
- 5.3.1 Global Cyclophosphamide Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Cyclophosphamide Revenue by Application (2021-2032)
- 5.3.3 Global Cyclophosphamide Revenue Market Share by Application (2021-2032)
6 Global Cyclophosphamide Sales by Region
- 6.1 Global Cyclophosphamide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cyclophosphamide Sales by Region (2021-2032)
- 6.2.1 Global Cyclophosphamide Sales by Region (2021-2026)
- 6.2.2 Global Cyclophosphamide Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cyclophosphamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Cyclophosphamide Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Cyclophosphamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Cyclophosphamide Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Cyclophosphamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Cyclophosphamide Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Cyclophosphamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Cyclophosphamide Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Cyclophosphamide Revenue by Region
- 7.1 Global Cyclophosphamide Revenue by Region
- 7.1.1 Global Cyclophosphamide Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Cyclophosphamide Revenue by Region (2021-2026)
- 7.1.3 Global Cyclophosphamide Revenue by Region (2027-2032)
- 7.1.4 Global Cyclophosphamide Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Cyclophosphamide Revenue (2021-2032)
- 7.2.2 North America Cyclophosphamide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Cyclophosphamide Revenue (2021-2032)
- 7.3.2 Europe Cyclophosphamide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Cyclophosphamide Revenue (2021-2032)
- 7.4.2 Asia-Pacific Cyclophosphamide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Cyclophosphamide Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Cyclophosphamide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Baxter
- 8.1.1 Baxter Company Information
- 8.1.2 Baxter Business Overview
- 8.1.3 Baxter Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Baxter Cyclophosphamide Product Portfolio
- 8.1.5 Baxter Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis Cyclophosphamide Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Hikma Pharmaceuticals
- 8.3.1 Hikma Pharmaceuticals Company Information
- 8.3.2 Hikma Pharmaceuticals Business Overview
- 8.3.3 Hikma Pharmaceuticals Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Hikma Pharmaceuticals Cyclophosphamide Product Portfolio
- 8.3.5 Hikma Pharmaceuticals Recent Developments
- 8.4 Amneal Pharmaceuticals LLC
- 8.4.1 Amneal Pharmaceuticals LLC Company Information
- 8.4.2 Amneal Pharmaceuticals LLC Business Overview
- 8.4.3 Amneal Pharmaceuticals LLC Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Amneal Pharmaceuticals LLC Cyclophosphamide Product Portfolio
- 8.4.5 Amneal Pharmaceuticals LLC Recent Developments
- 8.5 Jiangsu Hengrui Medicine
- 8.5.1 Jiangsu Hengrui Medicine Company Information
- 8.5.2 Jiangsu Hengrui Medicine Business Overview
- 8.5.3 Jiangsu Hengrui Medicine Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Jiangsu Hengrui Medicine Cyclophosphamide Product Portfolio
- 8.5.5 Jiangsu Hengrui Medicine Recent Developments
- 8.6 NorthStar Rx LLC
- 8.6.1 NorthStar Rx LLC Company Information
- 8.6.2 NorthStar Rx LLC Business Overview
- 8.6.3 NorthStar Rx LLC Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 NorthStar Rx LLC Cyclophosphamide Product Portfolio
- 8.6.5 NorthStar Rx LLC Recent Developments
- 8.7 GLS Pharma
- 8.7.1 GLS Pharma Company Information
- 8.7.2 GLS Pharma Business Overview
- 8.7.3 GLS Pharma Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GLS Pharma Cyclophosphamide Product Portfolio
- 8.7.5 GLS Pharma Recent Developments
- 8.8 CSC Pharmaceuticals International
- 8.8.1 CSC Pharmaceuticals International Company Information
- 8.8.2 CSC Pharmaceuticals International Business Overview
- 8.8.3 CSC Pharmaceuticals International Cyclophosphamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 CSC Pharmaceuticals International Cyclophosphamide Product Portfolio
- 8.8.5 CSC Pharmaceuticals International Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Cyclophosphamide Value Chain Analysis
- 9.1.1 Cyclophosphamide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Cyclophosphamide Production Mode & Process
- 9.2 Cyclophosphamide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Cyclophosphamide Distributors
- 9.2.3 Cyclophosphamide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst